Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock

B NEW YORK, April 23, 2026 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of…
posteditor
posteditor
Articles: 27509